Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
about
Modulation of Protein-Protein Interactions for the Development of Novel TherapeuticsSex differences in Parkinson's diseaseAlpha-synuclein and tau: teammates in neurodegeneration?Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicityWalking in fully immersive virtual environments: an evaluation of potential adverse effects in older adults and individuals with Parkinson’s diseaseBehavioral and neurophysiological correlates of striatal dopamine depletion: a rodent model of Parkinson's disease.Differential sensitivity of cranial and limb motor function to nigrostriatal dopamine depletion.Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine.Pain in Parkinson's disease associated with COMT gene polymorphismsMorbidity in early Parkinson's disease and prior to diagnosisDJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity.Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?Why psychosis is frequently associated with Parkinson's disease?Deep brain stimulation in Parkinson's diseasePsychiatric aspects of Parkinson's disease.Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease.Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties.Stress, depression and Parkinson's disease.Exposure to glyphosate- and/or Mn/Zn-ethylene-bis-dithiocarbamate-containing pesticides leads to degeneration of γ-aminobutyric acid and dopamine neurons in Caenorhabditis elegans.Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model AnalysisForce Variability during Dexterous Manipulation in Individuals with Mild to Moderate Parkinson's Disease.Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.The Natural Progression of Parkinson's Disease in a Small Cohort with 15 Drug-naïve Patients.Epigenetics-Based Therapeutics for Neurodegenerative Disorders.The relationship between quality of life and swallowing in Parkinson's diseaseMedication management and neuropsychological performance in Parkinson's diseaseCardiovascular physiology in premotor Parkinson's disease: a neuroepidemiologic studyMitochondrial dynamics in Parkinson's disease.The influence of facial masking and sex on older adults' impressions of individuals with Parkinson's disease.Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a reviewContinuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.Differences between conventional and nonconventional MRI techniques in Parkinson's disease.Young and middle-aged rats exhibit isometric forelimb force control deficits in a model of early-stage Parkinson's disease.A perfusion MRI study of emotional valence and arousal in Parkinson's disease.Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in miceAntioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease.What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy.Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.The neuroprotective role of melatonin in neurological disorders.
P2860
Q26775356-10BEF654-4ED3-4843-84CB-904B29A63AA5Q27025107-C282487B-1BE8-435C-9DEF-62FBEB1DF4C8Q28250508-86648AE8-27E1-4C53-8E39-00FBC13FDB04Q28388187-36363DB9-7FEA-4341-A46A-75DDA855A8D8Q29248134-3836C9D5-5D78-4FFF-8AAA-802061EFAFA8Q30395768-2396B7BC-18EA-48EF-95F3-C75A70DEEA73Q30444369-AC08B93F-3F00-4914-BC9F-1750289B26F8Q30478476-84AB1DB1-CEF0-4313-A577-71466EA64575Q33533358-7A816FD3-0FE6-4825-BFF5-CA91C9F166E5Q33552543-CDB2EFFD-D12B-4204-B838-FECF9B3A0865Q33746827-2FE1FEC6-08C0-4C55-B960-BF305D6870ADQ33755817-C32B0328-3C24-4D01-A8EA-C0C18DD3598BQ33785397-40AD09D9-7AE9-4FF1-81ED-A1E33DBDCFEEQ34094668-940FFC8E-1D48-4970-AE54-F30D39A2E708Q34255809-6F1FA3A0-4020-473F-9096-E6389C99C7A8Q34574771-408799D0-1821-4F3D-BC0F-FEBE497A4B83Q35058875-8CE1327F-AC11-40C2-B99A-12F97F532DB7Q35623461-6E466544-6BF2-4502-920B-4D072033CBADQ35713356-D787EB5E-E1B2-4466-84CC-0E743DC4E5EBQ35785033-ED967C97-F8E2-4347-A918-3484B7684796Q35876969-0CE66745-9775-45CB-9FAB-19106B9C9DF9Q35932534-3CB5612C-95CB-4D11-8EC6-4F861C9BFE60Q35971342-E7E5DC97-8137-44B1-9169-B1293C3AAAD3Q36523096-40C972E8-B8AE-457D-AB2F-2C5564C455F5Q36697733-AD88E597-1358-4B38-8B07-2B8DDF0DC545Q36734537-F2396445-FB0F-4089-A6B1-97DC5A97A09FQ36822919-FC0BFA7E-D161-40DA-A9E6-BEAF794134D0Q36838860-71D623F6-33F2-4373-97AA-26FE69B7E5EEQ37364337-08067D37-810C-4733-A4C0-DB874B1C1D8AQ37385654-DC2D4706-DEE3-4019-880D-5C2E5A129271Q37418238-4101C8A7-51A0-4EFB-89A4-BC613D4516C4Q38080952-5D5FE9F9-37F4-446F-BD75-108BB962DD7EQ38152514-CBCABB45-CD2A-4041-9251-3A9FE5CF503FQ38542752-19A4398A-945F-4910-B619-87E0D7B0D408Q38586316-F749C0D2-B380-4126-93C6-B0656AE7B012Q42268862-C2646190-EC84-4E98-B87C-A4647F3E0008Q42473221-536A7E3E-C6C8-4C0A-8FE9-047D2A484E61Q42749938-889081D4-763E-4B1F-A80F-48484210DC2BQ46205987-A8E2EAB6-C474-4C21-9775-05F03C6C919BQ53396094-1EFC81BF-644C-4455-9A51-788AE2EFF425
P2860
Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parkinson's disease--Part 1: P ...... en, diagnosis, and assessment.
@en
Parkinson's disease--Part 1: P ...... en, diagnosis, and assessment.
@nl
type
label
Parkinson's disease--Part 1: P ...... en, diagnosis, and assessment.
@en
Parkinson's disease--Part 1: P ...... en, diagnosis, and assessment.
@nl
prefLabel
Parkinson's disease--Part 1: P ...... en, diagnosis, and assessment.
@en
Parkinson's disease--Part 1: P ...... en, diagnosis, and assessment.
@nl
P2093
P921
P1476
Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment
@en
P2093
Cynthia L Comella
Daniel Weintraub
Stacy Horn
P433
P577
2008-03-01T00:00:00Z